Issue link: http://www.e-digitaleditions.com/i/853645
Particle size reduction services Catalent Micron Technologies is a global leader in particle size reduction services, delivering first-class micronization, milling and analytical services. Combined with quality and speed of response, Catalent Micron Technologies offers expertise for both oral and inhaled dosage forms. Its full range of capabilities includes development through to commercial scale; micronization (jet mill); mechanical milling (hammer mill, pin mill); cryogenic milling; controlled handling of potent and cytotoxic compounds, and comprehensive supporting analytical services. Catalent US: + 1 888 SOLUTION www.catalent.com/inhalation Advertiser index A Astech 7 C Capsugel 1 Copley Scientific 3 H Hovione 17 M Meggle Group Cover 2 MSP Cover 4 P Proveris Scientific 11 R RDD Europe 13 device platforms. This program is the first partnered collaboration to be announced from the planned series of projects. Novoteris receives clearances for phase 2 trial G A R D E N G R O V E , C A — PRNewswire reports that the US Food and Drug Administration and the erapeutic Products Director- ate of Health Canada have cleared a Phase 2 clinical trial application from Novoteris, LLC for its iola- nox® inhaled nitric oxide for the t r e a t m e n t o f c y s t i c f i b r o s i s ( C F ) . T h e c o m p a n y r e c e i v e d orphan drug designations for the treatment of cystic fibrosis from both the FDA and EMA in 2013. e company will begin recruiting for a five-site, multi-center trial that will randomize sixty subjects recruited from five cystic fibrosis research centers to use either iola- nox® nitric oxide or placebo, deliv- ered with its unique computerized trace-gas mixing system. A Phase 1 pilot trial in Europe reported encouraging microbiological and significant lung function changes following two weeks of the same treatment in patients with CF. Gas- eous nitric oxide's potent antimi- crobial properties, lack of bacterial resistance, and small molecule pen- etration capabilities could provide a promising alternative, non-antibi- otic approach to treating infections in CF patients. respirAtory Medicine news Novel links between type 1 diabetes and asthma HELSINKI, FINLAND—www. diabetes.co.uk. reports that diabe- tes and asthma have been previously linked, yet new research from Fin- land shows that having asthma increased the risk of developing type 1 diabetes by 41 percent, however the risk of those with type 1 diabetes developing asthma decreased by 18 p e r c e n t . L e a d r e s e a r c h e r D r . Johanna Metsala of the National Institute for Health and Welfare in Helsinki explained that the associa- tion was seen at all ages and "this was a fairly novel observation." All previous research had not shown conclusive evidence about the rela- tionship between asthma and type 1 diabetes. e team examined Finn- ish health records of children born between 1981 and 2008 who had either type 1 diabetes or asthma by the time they were aged 16 or the year 2010. They used a pool of 171,138 children as part of a sample representing 10 percent of young- sters born between those years. In total, 80,871 children had asthma, while 8,939 had been diagnosed with type 1 diabetes and 602 had both conditions. 50th anniversary of discovery of IgE UPPSALA, SWEDEN—Accord- ing to ermo Fisher Scientific, 2017 marks the 50th anniversary of the identification of the immu- noglobulin E (IgE) antibody by researchers at Uppsala University in Sweden. at provided the first measurable evidence of allergic response within the body and paved the way for allergy diagno- ses using simple blood tests. e discovery also triggered far-reach- ing advancements in allergy and asthma diagnosis and treatment that ensure patients can more rap- idly understand, manage and relieve their symptoms. Other advancements from the Uppsala site included the first commer- c i a l l y a v a i l a b l e t e s t f o r a l l e r - gen-specific IgE antibodies (now ImmunoCAP, a Thermo Fisher brand), the first radio-allergosor- bent test (RAST) for allergen-spe- cific IgE antibodies and the first integrated solution for handling, processing and measurement in one instrument. Today, ermo Fisher's family of allergen sensiti- zation and autoimmunity diag- nostic testing solutions—Phadia Laboratory Systems—enables labs to automate the processing of up to 40,000 tests per day. continued from page 7 26 August 2017 Inhalation